Thrombotic conditions, such as atrial fibrillation, stroke, myocardial infarction, deep vein thrombosis (DVT), and pulmonary embolism, are the leading causes of morbidity and mortality worldwide.1Current oral anticoagulants include vitamin K antagonists (warfarin) and direct oral anticoagulants that target serine proteases in the common coagulation pathway, such as thrombin (dabigatran) or factor Xa (FXa; apixaban, rivaroxaban, edoxaban, betrixaban). The gene discussed is F10; the disease is stroke disorder.